PDF icon PDF herunterladen
Open Access
CC BY 4.0 · Thromb Haemost
DOI: 10.1055/a-2595-1927
Stroke, Systemic or Venous Thromboembolism

Serum MPO-DNA for Predicting the Risk of Venous Thromboembolism and the Effect of Statins in Patients with Spontaneous Intracerebral Hemorrhage

Xinyan Yan
1   Department of Neurology, Hunan Provincial People's Hospital and The First-Affiliated Hospital of Hunan Normal University, Changsha, Hunan, People's Republic of China
,
Wenyan Huang
2   Department of Pulmonary and Critical Care Medicine, Hunan Provincial People's Hospital and The First-Affiliated Hospital of Hunan Normal University, Changsha, Hunan, People's Republic of China
,
Yunrong Chen 
2   Department of Pulmonary and Critical Care Medicine, Hunan Provincial People's Hospital and The First-Affiliated Hospital of Hunan Normal University, Changsha, Hunan, People's Republic of China
› Institutsangaben
Funding This work was supported by the Scientific Research Plan Project of the Health Commission of Hunan Province (202203023609, 202214015252) and the General Program of the Hunan Provincial Natural Science Foundation of China (2025JJ50671).
› Weitere Informationen
  Lizenzen und Reprints


Preview

Abstract

Background

Patients with spontaneous intracerebral hemorrhage (ICH) are at high risk of venous thromboembolism (VTE). Recent studies have shown the involvement of neutrophil extracellular traps (NETs) in thrombogenesis.

Objectives

To explore the predictive value of serum MPO-DNA (a NETs surrogate) for VTE and the effect of statins on serum MPO-DNA levels and the VTE incidence in ICH patients.

Methods

This prospective cohort study enrolled 117 ICH patients and 15 healthy controls. Serum MPO-DNA levels were measured via ELISA. The relationship between serum MPO-DNA levels and VTE risk was analyzed. The predictive value of MPO-DNA was evaluated by ROC curves. Effects of statin on NETs and VTE incidence were evaluated.

Results

The median MPO-DNA level in patients with VTE was 0.304 (95% CI: 0.231–0.349), significantly higher than the 0.188 (95% CI: 0.159–0.236) in non-VTE patients. Elevated MPO-DNA levels were associated with an increased VTE risk (OR 7.13, 95% CI 2.58–19.75; P < 0.001), and this association persisted after adjustment. The AUC values for MPO-DNA, CRP, and D-dimer were 0.824 (95% CI: 0.719–0.928), 0.618 (95% CI: 0.481–0.754), and 0.786 (95% CI: 0.683–0.888), respectively. Moreover, statin users exhibited reduced MPO-DNA levels (0.174 vs. 0.218; P = 0.007), though VTE incidence differences (13.8% vs. 19.3%) lacked statistical significance.

Conclusion

Serum MPO-DNA serves as a sensitive biomarker for VTE prediction in ICH, highlighting NETs as potential therapeutic targets. Statins could attenuate NETosis, but larger trials are required to validate their clinical efficacy and safety in VTE prevention for ICH patients.

Keywords

cerebral hemorrhage - neutrophil extracellular traps - MPO-DNA - venous thromboembolism - hydroxymethylglutaryl-CoA reductase inhibitors

Data Availability Statement

The data that support the findings of this study are available on reasonable request from the corresponding author.




Publikationsverlauf

Eingereicht: 08. März 2025

Angenommen: 23. April 2025

Accepted Manuscript online:
28. April 2025

Artikel online veröffentlicht:
09. Mai 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany